FDA Investigator Ngoc T Le
Ngoc T Le has conducted inspections on 59 sites in 1 countries as of 18 Jun 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
59
Last Inspection Date:
18 Jun 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Ngoc T Le:
Alejandra Mcclellan,
Alexandra B Pitkin,
Ana Djurdjevic,
Angela Shepas,
Angelica Ornelas,
Ashley S Ertzman,
Binh T Nguyen,
Burnsb,
Bush,
Cathleen A Carr Sharpe,
Celena Ngo,
Comyar Shoghi,
Cristina Resendiz Navarrete,
David G Whitman,
Davis,
Deborah W Hsu,
Debra J Fracassa,
Dejon N Harris,
Desiree C Iya,
Diana M Rand,
Djamila Harouaka,
Dyana K Stone,
Elaine S Chow,
Elizabeth Q Maccorkell,
Fe Q Reyes,
Francisco,
Garciam,
Geoffrey M Leist,
Geraldine M Peregrin,
Glen E Harelson,
Grace P Santos,
Greg K Keshishyan,
Gulshan R Anand,
Henry E Carrillo,
Herminio C Francisco,
Hunter M Vice,
Jacqueline O Snell,
James A Barreto,
James P Stallings,
Jane G Choi,
Jeff M Uriarte,
Jennifer Crumb,
Jennifer S King,
Jessica L Andrade,
Jinnie Kokiatkulkij,
Joan T Briones,
John A Liu,
John R Myung,
Jonathan K Dare,
Joseph C Francisco,
Joseph C Yen,
Joseph H Lam,
Joseph M Willems,
Judy C Nepsa,
Ka L Wong,
Karen L Bauer,
Kawshalya Pathiraja,
Kelvin X Sanders,
Kevin Lee,
Kimberly M Lichter,
Lilly O Barton,
Linda Thai,
Loretta J Jordan,
Macropolk,
Mark C Saale,
Maurice M Sheehan,
Melody M Ragasa Leong,
Michael D Garcia,
Michael S Call,
Michelle J Hines,
Michelle L Tripp,
Monica R Maxwell,
Natalie J Ayoub,
Nianna C Burns,
Nicholas J Lahey,
Patricia F Alberico,
Phillip J Sample,
Phillip L Toy,
Rachel V Leimbach,
Richard W Tubb,
Robert C Hoover,
Robert T Lorenz,
Rocio Guzman Velazquez,
Romero,
Ruben G Abrajano,
Saied A Asbagh,
Savannah E Samp,
Scott J Matsuda,
Sean P Desbrow,
Sonia R Peterson,
Sparky L Bartee,
Sundy V Sedwick,
Tammy Vasquez Hancock,
Tanya E Malais,
Tara L Stockton,
Tawny L Colling,
Thomas W Gordon,
Timothy P Lafave,
Trushani T Desai,
Tuan D Tran,
Vanessa R Muller,
William J Foust,
Yen Tso Kuo,
Yolanda D Mitchell Lee,
Yvette Mlacour Davis,
Zachary A Bogorad,
Zachary Ryan Harris
Ngoc T Le's Documents
Publish Date | Document Type | Title |
---|---|---|
May, 2021 | FDA 483 | OCPP LLC - Form 483, 2021-05-26 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more